Tuberculosis

REFERENCES

• Anon. (2004). AIDS Epidemic Update. December 2004. Geneva: World Health Organization.
   Google Scholar
• Anon. (2005). Progress on Global Access to HIV Antiretroviral Therapy. An Update on ‘3 by 5’. Geneva: World Health Organization.
   Google Scholar
• Badri, M., Wilson, D. & Wood, R. (2002). Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet, 359,2059–2064.
   PubMed Web of Science ®Google Scholar
• Chiba, Y. & Kurihara, T. (1979). Development of pulmonary tuberculosis with special reference to the time interval after tuberculin conversion. Bulletin of the International Union against Tuberculosis and Lung Disease, 54,263–264.
   Google Scholar
• Chintu, C., Bhat, G. J., Walker, A. S., Mulenga, V., Sinyinza, F., Lishimpi, K., Farrelly, L., Kaganson, N., Zumla, A., Gillespie, S. H., Nunn, A. N. & Gibb, D. M. (2004). Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised pla-cebo-controlled trial. Lancet, 364,1865–1871.
   PubMed Web of Science ®Google Scholar
• Churchyard, G. J., Fielding, K., Charalambous, S., Day, J. H., Corbett, E. L. Hayes, R. J., Chaisson, R. E., de Cock, K. M., Samb, B. & Grant, A. (2003). Efficacy of secondary isoniazid preventive therapy among HIV-infected southern Africans: time to change policy? AIDS, 17,1–8.
   PubMedGoogle Scholar
• Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C. & Dye, C. (2003). The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine, 163, 1009–1021.
   PubMed Web of Science ®Google Scholar
• Dye, C., Garnett, G. P., Sleeman, K. & Williams, B. G. (1998). Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet, 352,1886–1891 .
   PubMed Web of Science ®Google Scholar
• Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. (1999). Global burden of tuber-culosis: estimated incidence, prevalence and mortal-ity by country. Journal of the American Medical Association, 282, 677–686.
   PubMed Web of Science ®Google Scholar
• Dye, C., Watt, C. J., Bleed, D. M., Hosseini, S. M. & Raviglione, M. C. (2005). Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. Journal of the American Medical Association, 293, 2767-2775.
   Google Scholar
• Fitzgerald, D. W., Desvarieux, M., Severe, P., Joseph, P., Johnson, W. D. & Pape, J. W. (2000). Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a rando-mised trial. Lancet, 356, 1470–1474.
   PubMed Web of Science ®Google Scholar
• Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J. & Dye, C. (2003). Tuberculosis. Lancet, 362, 887–899.
   PubMed Web of Science ®Google Scholar
• Girardi, E., Antonucci, G., Vanacore, P., Libanore, M., Errante, I., Matteelli, A., Ippolito, G. & The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA) (2000). Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS, 14, 1985–1991.
   PubMed Web of Science ®Google Scholar
• Grant, A. D., Charalambous, S., Fielding, K. L., Day, J. H., Corbett, E. L., Chaisson, R. E., de Cock, K. M., Hayes, R. J. & Churchyard, G. J. (2005). Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa. A novel randomised incremental recruitment study. Journal of the American Medical Association, 293, 2719–2725.
   PubMed Web of Science ®Google Scholar
• Gutierrez, M. C., Brisse, S., Brosch, R., Fabre, M., Omai's, B., Marmiesse, M., Supply, P. & Vincent, V. (2005). Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis. PloS Pathogens, 1, e-Pub Aug 19.
   Google Scholar
• Haines, A. & Sanders, D. (2005). Building capacity to attain the Millennium Development Goals. Transactions of the Royal Society of Tropical Medicine and Hygiene, 99, 721–726.
   PubMed Web of Science ®Google Scholar
• Hargreaves, N. J., Kadzakumanja, O., Phiri, S., Nyangulu, D. S., Salaniponi, F. M. L., Harries, A. D. & Squire, S. B. (2001). What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence? International Journal of Tuberculosis and Lung Disease, 5,113–122.
   PubMed Web of Science ®Google Scholar
• Harries, A. D., Hargreaves, N. J., Graham, S. M., Mwansambo, C., Kazembe, P., Broadhead, R., Maher, D. & Salaniponi, F. M. (2001a). Childhood tuberculosis in Malawi: nationwide case-finding and treatment outcomes. International Journal of Tuberculosis and Lung Disease, 6, 424-431.
   Google Scholar
• Harries, A. D., Hargreaves, N. J., Kemp, J., Jindani, A., Enarson, D. A., Maher, D. & Salaniponi, F. M. (2001i). Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet, 357, 1519-1523.
   Google Scholar
• Harries, A. D., Zachariah, R., Bergstrom, K., Blanc, L., Salaniponi, F. M. & Elzinga, G. (2005). Human resources for control of tuberculosis and HIV-associated tuberculosis. International Journal of Tuberculosis and Lung Disease, 9, 128–137.
   PubMed Web of Science ®Google Scholar
• Hung, C.-C., Chen, M.-Y., Hsiao, C.-F., Hsieh, S.-M., Sheng, W.-H. & Chang, S.-C. (2003). Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS, 17, 2615–2622.
   PubMed Web of Science ®Google Scholar
• Korenromp, E. L., Scano, F., Williams, B. G., Dye, C. & Nunn, P. (2003). Effects of human immunodefi-ciency virus infection on recurrence of tuberculosis after rifampicin-based treatment: an analytic review. Clinical Infectious Diseases, 37,101–112.
   PubMed Web of Science ®Google Scholar
• Lambert, M.-L., Hasker, E., van Deun, A., Roberfroid, D., Boelaert, M. & van der Stuyft, P. (2003). Recurrence in tuberculosis: relapse or reinfection? Lancet Infectious Diseases, 3,282–287.
   PubMed Web of Science ®Google Scholar
• Lawn, S. D., Bekker, G.-L. & Miller, R. F. (2005). Immune reconstitution disease associated with myco-bacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infectious Diseases, 5, 361-373.
   Google Scholar
• Lewis, D. K., Whitty, C. J. M., Walsh, A. L., Epino, H., van den Broek, N. R., Letsky, E. A., Munthali, C., Mukiibi, J. M. & Boeree, M. J. (2005). Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV prevalence. Transactions of the Royal Society of Tropical Medicine an d Hygiene, 99, 561-567.
   Google Scholar
• Lucas, S. B., de Cock, K. M., Hounnou, A., Peacock, C., Diomande, M., Honde, M., Beaumel, A., Kesters, L. & Kadio, A. (1994). Contribution of tuberculosis to slim disease in Africa. British Medical Journal, 308, 1531–1533.
   PubMed Web of Science ®Google Scholar
• Maher, D., van Gorkom, J. L. C., Gondrie, P. C. F. M. & Raviglione, M. (1999). Community contribution to tuberculosis care in countries with high tubercu-losis prevalence: past, present and future. International Journal of Tuberculosis and Lung Disease, 3, 762-768.
   Google Scholar
• Mermin, J., Lule, J., Ekwaru, J. P., Malamba, S., Downing, R., Ransom, R., Kaharuza, F., Culver, D., Kizito, F., Bunnell, R., Kigozi, A., Nakanjako, D., Wafula, W. & Quick, R. (2004). Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet, 364, 1428–1434.
   PubMed Web of Science ®Google Scholar
• Murray, C. J. L., Styblo, K. & Rouillon, A. (1990). Tuberculosis in developing countries: burden, inter-vention and cost. Bulletin of the International Union against Tuberculosis and Lung Disease, 65, 6–24.
   PubMedGoogle Scholar
• Nunn, P., Kibuga, D., Gathua, S., Brindle, R., Imalingat, A., Wasunna, K., Lucas, S., Gilks, C., Omwega, M., Were, J. & McAdam, K. (1991). Cutaneous hypersensitivity reactions due to thiace-tazone in HIV-1 seropositive patients treated for tuberculosis. Lancet, 337, 627–630.
   PubMed Web of Science ®Google Scholar
• Pedro-Botet, J., Gutierrez, J., Miralles, R., Coll, J. & Rubies-Prat, J. (1992). Pulmonary tuberculosis in HIV-infected patients with normal chest radiographs. AIDS, 6, 91–93 .
   PubMed Web of Science ®Google Scholar
• Pozniak, A. L., Miller, R. & Ormerod, L. P. (1999). The treatment of tuberculosis in HIV-infected patients. AIDS, 13, 435-445.
   Google Scholar
• Quigley, M. A., Mwinga, A., Hosp, M., Lisse, I., Fuchs, D., Porter, J. D. H. & Godfrey-Faussett, P. (2001). Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS, 15, 215–222.
   PubMed Web of Science ®Google Scholar
• Raviglione, M. C. & Pio, A. (2002). Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet, 359, 775-780.
   Google Scholar
• Raviglione, M. C., Harries, A. D., Msiska, R., Wilkinson, D. & Nunn, P. (1997). Tuberculosis and HIV: current status in Africa. AIDS, 11 (Suppl. B), S115-S123.
   Google Scholar
• Richter, C., Ndosi, B., Mwammy, A. S. & Mbwambo, R. K. (1991). Extrapulmonary tuberculosis - a simple diagnosis? Tropical and Geographical Medicine, 43, 375–378.
   PubMedGoogle Scholar
• Roberts, C. A. & Buikstra, J. E. (2003). The history of tuberculosis from earliest times to the development of drugs. In Clinical Tuberculosis, 3rd Edn, ed. Davies, P. D. O. pp. 3-20. London: Arnold.
   Google Scholar
• Sonnenberg, P., Glynn, J. R., Fielding, K., Murray, J., Godfrey-Faussett, P. & Shearer, S. (2005). How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. Journal of Infectious Diseases, 191, 150–158.
   PubMed Web of Science ®Google Scholar
• Suaerez, P. G., Floyd, K., Portocarrero, J., Alarcon, E., Rapiti, E., Ramos, G., Bonilla, C., Sabogal, I., Aranda, I., Dye, C., Raviglione. M. & Espinal, M. A. (2002). Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet, 359, 1980–1989.
   PubMed Web of Science ®Google Scholar
• Styblo, K. & Bumgarner, J. R. (1991). Tuberculosis can be controlled with existing technologies: evi-dence. Tuberculosis Research Unit Progress Report, 2, 60–72.
   Google Scholar
• Sutherland, I. (1976). Recent studies in the epidemiol-ogy of tuberculosis, based on the risk of being infected with tubercle bacilli. Advances in Tuberculosis Research, 19, 1–63.
   PubMedGoogle Scholar
• Toungoussova, O. S., Nizovtseva, N. I., Mariandyshev, A. O., Caugant, D. A., Sandven, P. & Bjune, G. (2004). Impact of drug-resistant Mycobacterium tuberculosis on treatment outcome of culture-positive cases of tuberculosis in the Archangel oblast, Russia, in 1999. European Journal of Clinical Microbiology and Infectious Diseases, 23, 174–179.
   PubMed Web of Science ®Google Scholar
• Wiktor, S. Z., Sassan-Morokro, M., Grant, A. D., Abouya, L., Karon, J. M., Maurice, C., Djomand, G., Ackah, A., Domoua, K., Kadio, A., Yapi, A., Combe, P., Tossou, O., Roels, T. H., Lackritz, E. M., Coulibaly, D., de Cock, K. M., Coulibaly, I. M. & Greenberg, A. E. (1999). Efficacy of trimethoprim-sulphamethoxazole prophlyaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled study. Lancet, 353, 1469–1475.
   PubMed Web of Science ®Google Scholar
• Wilkinson, D., Squire, S. B. & Garner, P. (1998). Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. British Medical Journal, 317, 625–629.
   PubMedGoogle Scholar
• Williams, B. G. & Dye, C. (2003). Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science, 301, 1535–1537.
   PubMed Web of Science ®Google Scholar
• World Health Organization (1994). Global Tuberculosis Programme. Framework for Effective Tuberculosis Control. Document WHO/TB/94.179. Geneva: WHO.
   Google Scholar
• World Health Organization (1996). Guidelines for the Management of Drug-resistant Tuberculosis. Document WHO/TB/96.219 (Rev.1). Geneva: WHO.
   Google Scholar
• World Health Organization (1998a). Policy Statement on Preventive Therapy Against Tuberculosis in People Living with HIV. Geneva: WHO.
   Google Scholar
• World Health Organization (1998b). Guidelines for the Control of Tuberculosis in Prisons. Document WHO/ TB/98.250. Geneva: WHO.
   Google Scholar
• World Health Organization (1999a). Preventive ther-apy against tuberculosis in people living with HIV. Weekly Epidemiological Record, 74, 385–400.
   PubMedGoogle Scholar
• World Health Organization (1999b). Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings. Document WHO/TB/ 99.269. Geneva: WHO.
   Google Scholar
• World Health Organization (2000a). Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of Multi-drug Resistant Tuberculosis [MDR-TB]. Document WHO/CDS/TB/2000.279. Geneva: WHO.
   Google Scholar
• World Health Organization (2000b). Fifty-third World Health Assembly. Stop TB Initiative, Report by the Director-General. A5315, 5 May 2000; Resolution WHA53.1. Geneva: WHO.
   Google Scholar
• World Health Organization (2000c). Provisional WHOIUNAIDS Secretariat Recommendations on the Use of Cotrimoxazole Prophylaxis in Adults and Children Living with HIVIAIDS in Africa. Geneva: WHO.
   Google Scholar
• World Health Organization (2003). Treatment of Tuberculosis. Guidelines for National Programmes. Document WHO/CDS/TB 2003.313. Geneva: WHO.
   Google Scholar
• World Health Organization (2004a). TBIHIV. A Clinical Manual, 2nd Edn. Document WHO/HTM/ TB/2004.329. Geneva: WHO.
   Google Scholar
• World Health Organization (2004b). Interim Policy on Collaborative TBIHIV Activities. Stop TB Department and Department of HIVIAIDS. Document WHO/ HTM/TB/2004.330. Geneva: WHO.
   Google Scholar
• World Health Organization (2004c). Guidelines for HIV Surveillance among Tuberculosis Patients, 2nd Edn. Document WHO/HTM/TB/2004.339. Geneva: WHO.
   Google Scholar
• World Health Organization (2004d). Report of a ‘Lessons Learnt’ Workshop on the Six PROTEST Pilot Projects in Malawi, South Africa and Zambia. Document WHO/HTM/TB/2004.336. Geneva: WHO.
   Google Scholar
• World Health Organization (2005). WHO Report 2005. Global Tuberculosis Control. Surveillance, Planning, Financing. Document WHO/HTM/TB/2005.349. Geneva: WHO.
   Google Scholar
• World Health Organization (2006). Global Plan to Stop TB 2006-2015. Document WHO/HTM/TB/ 2006.35. Geneva: WHO.
   Google Scholar
• Zachariah, R., Spielmann, M.-P., Chinji, C., Gomani, P., Arendt, V., Hargreaves, N. J., Salaniponi, F. M. L. & Harries, A. D. (2003). Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS, 17, 1053-1061.
   Google Scholar